6901 Stock Overview
A venture capital firm specializing in evergreen funds. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Diamond Biofund Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$32.05 |
| 52 Week High | NT$49.75 |
| 52 Week Low | NT$31.10 |
| Beta | 1.51 |
| 1 Month Change | -1.99% |
| 3 Month Change | -19.07% |
| 1 Year Change | -31.74% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -83.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6901 | TW Capital Markets | TW Market | |
|---|---|---|---|
| 7D | -6.6% | -0.6% | 0.9% |
| 1Y | -31.7% | 19.0% | 28.9% |
Return vs Industry: 6901 underperformed the TW Capital Markets industry which returned 19% over the past year.
Return vs Market: 6901 underperformed the TW Market which returned 28.9% over the past year.
Price Volatility
| 6901 volatility | |
|---|---|
| 6901 Average Weekly Movement | 5.8% |
| Capital Markets Industry Average Movement | 2.3% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6901 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6901's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 28 | Yolanda Wu | www.diamondbiofund.com/tc/index.htm |
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology.
Diamond Biofund Inc. Fundamentals Summary
| 6901 fundamental statistics | |
|---|---|
| Market cap | NT$28.07b |
| Earnings (TTM) | -NT$1.56b |
| Revenue (TTM) | n/a |
-19.4x
P/S Ratio-17.5x
P/E RatioIs 6901 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6901 income statement (TTM) | |
|---|---|
| Revenue | -NT$1.41b |
| Cost of Revenue | NT$0 |
| Gross Profit | -NT$1.41b |
| Other Expenses | NT$154.36m |
| Earnings | -NT$1.56b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | 110.97% |
| Debt/Equity Ratio | 0% |
How did 6901 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 11:51 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Diamond Biofund Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|